Vaccine Templates

Vaccine templates serve as standardized tools that incorporate essential factors for conducting a risk/benefit assessment of new vaccine candidates. Their primary objectives are:

To facilitate communication of otherwise complex and highly technical data among key stakeholders and increase the transparency, comparability, and comprehension of essential information.

To offer a practical checklist-like resource for effectively managing potential complex risks.

To focus on key questions related to the essential safety and benefit-risk issues relevant for the intrinsic properties of the vaccine components. Below, you will find a comprehensive list of available standardized templates, as well as a selection of completed templates that have been utilized.

These have been developed with the collaboration of the Brighton Collaboration BRAVATO Working Group. Learn more HERE.

See the Brighton Collaboration standarized templates:

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines

Template for the Evaluation of Vaccines for Maternal Immunization

See the completed standarized templates:

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses